An Open-Label, Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
Incyte Corporation
Summary
The purpose of this study is to evaluate the interstitial concentrations using the open-flow microperfusion device and plasma pharmacokinetics following multiple doses of povorcitinib or topical ruxolitinib cream in healthy adult participants.
Eligibility
- Age range
- 18–65 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Ability to comprehend and willingness to sign a written ICF for the study. * Aged 18 to 65 years, inclusive, at the time of signing the ICF. * Body mass index between 18.0 and 30.5 kg/m2, inclusive. * No clinically significant findings on screening evaluations (clinical, laboratory, and ECG). * Ability to swallow and retain oral medication. * Willingness to avoid pregnancy or fathering children. Exclusion Criteria: * History of uncontrolled or unstable cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disea…
Interventions
- DrugPovorcitinib
Oral; Tablet
- DrugRuxolitinib
Ruxolitinib cream applied topically.
Location
- Axis ClinicalsDilworth, Minnesota